|
SG11201504558TA
(en)
|
2012-12-11 |
2015-07-30 |
Einstein Coll Med |
Methods for high throughput receptor:ligand identification
|
|
KR102493543B1
(ko)
*
|
2014-07-21 |
2023-01-30 |
데리니아, 인크. |
자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
|
|
JP6640834B2
(ja)
|
2014-08-11 |
2020-02-05 |
デリニア， インコーポレイテッド |
自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
|
|
IL304950A
(en)
|
2015-04-10 |
2023-10-01 |
Amgen Inc |
Interleukin for the expansion of myotonic control T-2 cells
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
KR20240115933A
(ko)
*
|
2016-05-04 |
2024-07-26 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
SG11201808552XA
(en)
|
2016-05-18 |
2018-10-30 |
Cue Biopharma Inc |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
IL262606B2
(en)
|
2016-05-18 |
2023-04-01 |
Albert Einstein College Medicine Inc |
pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
|
|
EP3538548A4
(en)
*
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
CN110177564A
(zh)
*
|
2016-12-13 |
2019-08-27 |
德里尼亚公司 |
多价的调节t细胞调节剂
|
|
CN110325205B
(zh)
|
2016-12-22 |
2023-08-15 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
US11851471B2
(en)
|
2017-01-09 |
2023-12-26 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
KR20240005989A
(ko)
|
2017-03-15 |
2024-01-12 |
큐 바이오파마, 인크. |
면역 반응을 조절하는 방법
|
|
JP7001285B2
(ja)
*
|
2017-03-29 |
2022-01-19 |
国立大学法人 宮崎大学 |
長時間作用型アドレノメデュリン誘導体
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
KR102777151B1
(ko)
|
2017-11-21 |
2025-03-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
인터루킨-2의 부분 효능제
|
|
KR20240115352A
(ko)
*
|
2017-12-06 |
2024-07-25 |
팬디온 오퍼레이션스, 인코포레이티드 |
Il-2 뮤테인 및 그 용도
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたｉｌ－２ ｆｃ融合タンパク質
|
|
CN111868079B
(zh)
|
2017-12-27 |
2025-06-17 |
协和麒麟株式会社 |
Il-2变体
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2019144309A1
(en)
*
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine Fusion Proteins
|
|
JP7534215B2
(ja)
|
2018-01-24 |
2024-08-14 |
ベイジン パーカンズ オンコロジー カンパニー リミテッド |
サイトカイン融合タンパク質
|
|
EP3752178A1
(en)
|
2018-02-16 |
2020-12-23 |
Iltoo Pharma |
Use of interleukin 2 for treating sjögren's syndrome
|
|
PE20210313A1
(es)
|
2018-03-28 |
2021-02-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
|
|
EP3552738B1
(en)
*
|
2018-04-12 |
2024-07-31 |
Sandvik Machining Solutions AB |
A method of producing an additive manufactured object
|
|
AU2019288496B2
(en)
|
2018-06-22 |
2024-11-21 |
Cugene Inc. |
Interleukin-2 variants and methods of uses thereof
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
WO2020023702A1
(en)
|
2018-07-25 |
2020-01-30 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
KR20210055694A
(ko)
|
2018-08-06 |
2021-05-17 |
메디카인 인코포레이티드 |
Il-2 수용체 결합 화합물
|
|
EP3836954B1
(en)
|
2018-08-13 |
2025-05-07 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
TW202034945A
(zh)
|
2018-12-21 |
2020-10-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種人白細胞介素２變體或其衍生物
|
|
CN113474370B
(zh)
|
2019-02-01 |
2025-04-01 |
瑞泽恩制药公司 |
抗IL2受体γ抗原结合蛋白
|
|
CN119708241A
(zh)
|
2019-02-15 |
2025-03-28 |
因特格尔莫来库乐有限公司 |
密封蛋白6抗体及其用途
|
|
US11254736B2
(en)
|
2019-02-15 |
2022-02-22 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
CN114341189A
(zh)
|
2019-06-12 |
2022-04-12 |
奥美药业有限公司 |
全新il-15前药及其应用
|
|
PH12022550165A1
(en)
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
EP4013775A1
(en)
*
|
2019-08-12 |
2022-06-22 |
Askgene Pharma, Inc. |
Il-2 fusion proteins that preferentially bind il-2ralpha
|
|
CN114555634B
(zh)
|
2019-08-13 |
2025-01-10 |
美国安进公司 |
用于扩增调节性t细胞的白介素-2突变蛋白
|
|
CA3160466A1
(en)
|
2019-11-05 |
2021-05-14 |
Medikine, Inc. |
Dual il-2r and il-7r binding compounds
|
|
MX2022005411A
(es)
|
2019-11-05 |
2022-08-10 |
Medikine Inc |
COMPUESTOS DE UNIÓN A IL-2RßYC.
|
|
US20230036793A1
(en)
|
2019-12-12 |
2023-02-02 |
Iltoo Pharma |
Interleukin 2 chimeric constructs
|
|
IL293978A
(en)
*
|
2019-12-20 |
2022-08-01 |
Regeneron Pharma |
New il2 agonists and methods of using them
|
|
AU2021205981A1
(en)
|
2020-01-11 |
2022-07-14 |
AskGene Pharma, Inc. |
Novel masked cytokines and methods of use thereof
|
|
CN115362168A
(zh)
|
2020-01-14 |
2022-11-18 |
辛德凯因股份有限公司 |
偏向化il2突变蛋白方法和组合物
|
|
AU2021217959A1
(en)
|
2020-02-03 |
2022-08-18 |
Medikine, Inc. |
IL-7Rα binding compounds
|
|
US11746139B2
(en)
|
2020-02-03 |
2023-09-05 |
Medikine, Inc. |
IL-7Rαγc binding compounds
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
US11028132B1
(en)
|
2020-04-07 |
2021-06-08 |
Yitzhak Rosen |
Half-life optimized linker composition
|
|
IL296209A
(en)
|
2020-05-12 |
2022-11-01 |
Cue Biopharma Inc |
Multimeric t-cell modulatory polypeptides and methods of using them
|
|
KR20230010251A
(ko)
|
2020-05-13 |
2023-01-18 |
보넘 테라퓨틱스, 인크. |
단백질 복합체의 조성물 및 그의 사용 방법
|
|
KR20230060514A
(ko)
*
|
2020-09-01 |
2023-05-04 |
다케다 야쿠힌 고교 가부시키가이샤 |
인터루킨-2 뮤테인 및 이의 용도
|
|
JP2023541366A
(ja)
|
2020-09-09 |
2023-10-02 |
キュー バイオファーマ， インコーポレイテッド |
１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
KR20230112632A
(ko)
|
2020-10-23 |
2023-07-27 |
애셔 바이오테라퓨틱스, 인크. |
면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
|
|
US20240325495A1
(en)
|
2020-10-29 |
2024-10-03 |
Bristol-Myers Squibb Company |
Fusion proteins for the treatment of disease
|
|
US20230398183A1
(en)
|
2020-11-13 |
2023-12-14 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof
|
|
CA3203977A1
(en)
|
2020-12-04 |
2022-06-09 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
IL304365B2
(en)
|
2021-03-31 |
2025-04-01 |
Hanmi Pharmaceutical Co Ltd |
A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
|
|
KR20230167405A
(ko)
|
2021-04-09 |
2023-12-08 |
셀렉타 바이오사이언시즈, 인크. |
면역 관용을 증진시키기 위해 고친화도 il-2 수용체 효능제와 조합된 면역억제제를 포함하는 합성 나노담체
|
|
CN118414160A
(zh)
|
2021-10-06 |
2024-07-30 |
艾尔图制药公司 |
对发炎组织具有靶向特异性的白介素2嵌合构建体
|
|
TW202333772A
(zh)
|
2021-12-01 |
2023-09-01 |
美商威特拉公司 |
使用介白素-2藥劑之方法
|
|
US20230263906A1
(en)
|
2022-01-10 |
2023-08-24 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
|
|
US20250082777A1
(en)
|
2022-01-10 |
2025-03-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023172628A1
(en)
|
2022-03-09 |
2023-09-14 |
Selecta Biosciences, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
|
|
WO2023183568A1
(en)
|
2022-03-25 |
2023-09-28 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
US11999771B2
(en)
|
2022-04-07 |
2024-06-04 |
Medikine, Inc. |
IL-7Rαγc ligand immunoglobulin fusion proteins
|
|
WO2023196566A1
(en)
|
2022-04-08 |
2023-10-12 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
|
|
CN115322260B
(zh)
*
|
2022-06-13 |
2026-02-10 |
杭州高田生物医药有限公司 |
能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用
|
|
AU2022477937A1
(en)
|
2022-09-12 |
2025-04-10 |
Assistance Publique - Hôpitaux De Paris |
Interleukin-2 for use in treating autism spectrum disorder
|
|
CN120282987A
(zh)
|
2022-11-30 |
2025-07-08 |
因特格尔莫来库乐有限公司 |
包括双特异性型式的针对紧密连接蛋白6的抗体
|
|
WO2024151515A2
(en)
|
2023-01-09 |
2024-07-18 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2024229370A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Compositions and methods for treating gvhd
|
|
WO2024229350A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
|
|
WO2024229380A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
|
|
WO2024229432A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2026006809A1
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Multispecific molecules binding tnfr2 and cd25 and uses thereof
|
|
WO2026159300A1
(en)
|
2025-01-24 |
2026-07-30 |
Iltoo Pharma |
M3c65 antibody and derivatives thereof for targeting inflammation
|